Immune Peptides and Aging Biology: Thymosin Alpha-1 and MOTS-c

The thymus and its peptides

The thymus is a small gland sitting behind the sternum that plays a central role in T cell maturation. T cells produced in the bone marrow travel to the thymus, where they undergo selection and are educated to distinguish self from non-self. The gland is most active in childhood and adolescence, after which it gradually shrinks in a process called thymic involution.

In the 1960s and 1970s, researchers studying the thymus extracted proteins from thymic tissue and tested them for biological activity. Allan Goldstein and colleagues at George Washington University isolated a family of small peptides from bovine thymus, collectively called thymosins. Thymosin alpha-1 was eventually identified as a naturally occurring cleavage product of a larger precursor protein called prothymosin alpha.

Synthetic thymosin alpha-1 is a 28 amino acid peptide with an acetylated N-terminus, manufactured today by solid-phase peptide synthesis. The compound became the basis for a pharmaceutical product called Zadaxin, developed and marketed by SciClone Pharmaceuticals.

What the thymosin alpha-1 clinical trials show

Thymosin alpha-1 has one of the larger clinical research records among peptides in its class. Because it is not approved in the United States, the trial landscape is spread across multiple countries and indications, which makes it harder to summarize than a compound with a single approved use and a straightforward regulatory dossier.

The main regulatory conclusion is clear: enough positive data existed across hepatitis indications for approval in over 30 countries, while the FDA and EMA have not found the totality of evidence sufficient for approval in their markets. This is a difference in regulatory threshold, trial design standards, and evidence requirements, not necessarily a scientific verdict that thymosin alpha-1 is ineffective.

How thymosin alpha-1 is thought to work

Thymosin alpha-1 is described in the published literature as an immune modulator rather than a direct antiviral or antimicrobial agent. Its effects are mediated through the host immune system, not through direct action on pathogens.

• •Reported to influence maturation and differentiation of T cells in the thymic environment
• •Published research describes effects on dendritic cell function and antigen presentation capacity
• •Interactions with toll-like receptor signaling pathways reported in preclinical studies
• •May shift the balance between pro-inflammatory and regulatory immune responses, though the specifics depend on experimental context
• •Unlike cytokines, which act through defined high-affinity receptors, the precise primary receptor for thymosin alpha-1 has not been fully characterized

MOTS-c and the mitochondrial genome

MOTS-c stands for Mitochondrial Open reading frame of the Twelve S rRNA-c. The name describes exactly where it comes from: a short open reading frame nested inside the region of mitochondrial DNA that encodes the 12S ribosomal RNA subunit. For most of the history of molecular biology, this region was assumed to encode only the structural RNA needed for mitochondrial translation, not any peptides. That assumption turned out to be wrong.

In 2015, Changhan Lee and Pinchas Cohen at the University of Southern California Leonard Davis School of Gerontology published a paper in Cell Metabolism describing the identification and characterization of MOTS-c. The discovery was part of a broader research program examining small open reading frames in mitochondrial DNA, inspired by the earlier finding of another mitochondrial-derived peptide called humanin.

MOTS-c mechanism and preclinical research

Research since the 2015 discovery has described MOTS-c as acting through AMP-activated protein kinase, or AMPK, a cellular energy sensor that is activated when ATP levels fall relative to AMP. AMPK activation generally promotes catabolic processes and suppresses anabolic ones, improving insulin sensitivity and promoting glucose uptake. MOTS-c is proposed to feed into this pathway by influencing folate-methionine metabolism and the resulting changes in purine biosynthesis intermediates.

• •Preclinical mouse studies reported improvements in insulin sensitivity and resistance to weight gain on high-fat diets with MOTS-c administration
• •Exercise studies in mice reported enhanced physical performance and changes in metabolic gene expression
• •Circulating MOTS-c levels have been reported to decline with age in some human observational studies
• •Under cellular stress conditions, MOTS-c has been reported to translocate to the nucleus and interact with gene regulatory elements, which is unusual for a peptide of its size
• •The researchers have proposed MOTS-c as a potential contributor to the metabolic benefits of exercise, with plasma levels rising in response to physical activity

All of the detailed mechanistic work described above comes primarily from cell and animal models and from the research group that discovered the peptide. Independent replication at the level of human clinical trials has not yet been published. That does not make the preclinical findings wrong, but it does mean the evidence base for MOTS-c remains early stage.

Comparing the two evidence bases

Thymosin alpha-1 and MOTS-c occupy very different positions on the research maturity spectrum, and understanding that difference matters for anyone evaluating these compounds.

The contrast is useful. Thymosin alpha-1 has the kind of clinical record that can inform a physician conversation and supports a regulatory dossier in multiple jurisdictions. MOTS-c is scientifically interesting but at a stage where extrapolation from rodent models to human administration involves substantial uncertainty.

Regulatory status and sourcing context

Thymosin alpha-1 is approved as Zadaxin in more than 30 countries for specific indications. In the United States, it is not FDA approved and is not available as a licensed prescription medication. It has been used in compassionate use contexts and has been available through compounding pharmacies at various times, though its compounding status has been subject to regulatory review.

MOTS-c has no regulatory approval anywhere for any indication. It is available as a research peptide from suppliers who sell it for laboratory use only. As with all research peptides, identity and purity cannot be verified without independent analytical testing, and the absence of an approved prescribing information document means there is no regulatory basis for dosing guidance.

Both compounds are absent from the current WADA Prohibited List by name, but athletes subject to anti-doping rules should review the annual list and their sport's specific regulations. The WADA S2 category covering peptide hormones, growth factors, and related substances is written broadly enough that specific new peptides may fall under it even without being listed by name.

Compound reference pages